AXSMNasdaqPharmaceutical PreparationsFiscal year ends December 31

Axsome Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026

$155.81−1.33 (-0.85%)

Close on Oct 19, 2026

Market cap: $8.07B
P/E (TTM): –
Dividend yield: –

Axsome Therapeutics, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31
Revenue	638	386	271	50	–	–	–	–	–	–	–	–
Cost of Revenue	47	33	26	5.20	–	–	–	–	–	–	–	–
Gross Profit	591	352	245	45	–	–	–	–	–	–	–	–
Research & Development	183	187	98	58	58	70	54	23	20	21	6.78	4.28
Selling, General & Admin	571	411	323	159	67	29	–	–	–	–	–	–
Selling & Marketing	440	293	237	105	–	–	–	–	–	–	–	–
General & Administrative	63	54	37	25	67	29	14	9.35	7.21	6.34	2.42	1.39
Advertising Expenses	167	101	100	35	–	–	–	–	–	–	–	–
Operating Expenses	–	–	–	–	125	99	67	33	27	28	9.20	5.67
Total Costs & Expenses	805	666	502	230	125	99	–	–	–	–	–	–
Operating Income	-167	-281	-232	-180	-125	-99	-67	-33	-27	-28	-9.20	-5.67
Interest Expense	-16	-22	-20	-9.66	–	–	–	–	–	–	–	–
Pretax Income	-184	-287	-238	-187	-130	–	–	–	–	–	–	–
Income Tax Expense	-0.53	0.09	0.96	0	0	0	0	0	0	0	–	–
Net Income incl. Noncontrolling Interests	-183	-287	-239	-187	-130	-103	-68	-31	-29	-27	–	–
Net Income	-183	-287	-239	-187	-130	-103	-68	-31	-29	-27	-12	-6.00
EPS (Basic)(per share)	-3.68	-5.99	-5.27	-4.60	-3.47	-2.77	-2.01	-1.15	-1.27	-1.42	-1.02	-0.66
EPS (Diluted)(per share)	-3.68	-5.99	-5.27	-4.60	-3.47	-2.77	-2.01	-1.15	-1.27	-1.42	-1.02	-0.66
Shares Outstanding (Basic, Weighted)(shares)	50	48	45	41	38	37	34	27	23	19	12	9.10
Shares Outstanding (Diluted, Weighted)(shares)	50	48	45	41	38	37	34	27	23	19	12	9.10

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 93.2%
Operating margin: -24.0%
Net margin: -24.7%
Return on equity, FY2025: -252.1%

Financial strength

Current ratio: 1.43
Debt to equity: 2.26
Debt to assets: 24.7%
Cash to current liabilities: 69.5%

Valuation

P/E ratio: –
Price to sales: 10.39
Price to book: 96.89
Dividend yield: –